JP2010508363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508363A5 JP2010508363A5 JP2009535437A JP2009535437A JP2010508363A5 JP 2010508363 A5 JP2010508363 A5 JP 2010508363A5 JP 2009535437 A JP2009535437 A JP 2009535437A JP 2009535437 A JP2009535437 A JP 2009535437A JP 2010508363 A5 JP2010508363 A5 JP 2010508363A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- membered
- heterocyclyl
- heteroaryl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001931 aliphatic group Chemical group 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000002723 alicyclic group Chemical group 0.000 claims description 28
- 150000002431 hydrogen Chemical group 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 102000042838 JAK family Human genes 0.000 claims description 6
- 108091082332 JAK family Proteins 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 201000001881 impotence Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 4
- 208000006029 Cardiomegaly Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000010410 reperfusion Effects 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- -1 1,2-methylenedioxy Chemical group 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 2
- 241000239366 Euphausiacea Species 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010019842 Hepatomegaly Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000003782 Raynaud disease Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 2
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 2
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 2
- 206010047163 Vasospasm Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000008694 endothelial dysfunction Effects 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 125000006161 haloaliphatic group Chemical group 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 230000014511 neuron projection development Effects 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- KZEDBHGMDQYYNT-UHFFFAOYSA-N C(C(c1c[nH]2)Nc(cccc3)c3-c3c1c2ncn3)OCc1ccccc1 Chemical compound C(C(c1c[nH]2)Nc(cccc3)c3-c3c1c2ncn3)OCc1ccccc1 KZEDBHGMDQYYNT-UHFFFAOYSA-N 0.000 description 1
- LXEVBBVJFDSXQF-UHFFFAOYSA-N C(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)c1ccccc1 Chemical compound C(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)c1ccccc1 LXEVBBVJFDSXQF-UHFFFAOYSA-N 0.000 description 1
- XXABPNQNJUEFOF-UHFFFAOYSA-N C1Oc2cc(C(c3c[nH]4)Nc5ccccc5-c5c3c4ncc5)ccc2O1 Chemical compound C1Oc2cc(C(c3c[nH]4)Nc5ccccc5-c5c3c4ncc5)ccc2O1 XXABPNQNJUEFOF-UHFFFAOYSA-N 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- PMZGUHFIOUYAPZ-UHFFFAOYSA-N FC(c1c(C2Nc3ccccc3-c3ccnc4c3c2c[nH]4)c(F)ccc1)(F)F Chemical compound FC(c1c(C2Nc3ccccc3-c3ccnc4c3c2c[nH]4)c(F)ccc1)(F)F PMZGUHFIOUYAPZ-UHFFFAOYSA-N 0.000 description 1
- ZGTRBSABWYYFNJ-UHFFFAOYSA-N Fc(c(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)c1F)ccc1F Chemical compound Fc(c(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)c1F)ccc1F ZGTRBSABWYYFNJ-UHFFFAOYSA-N 0.000 description 1
- RUDQSTSEVNDVSX-UHFFFAOYSA-N Fc(cc(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)cc1)c1Cl Chemical compound Fc(cc(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)cc1)c1Cl RUDQSTSEVNDVSX-UHFFFAOYSA-N 0.000 description 1
- JWPFBCRJPHMGGQ-UHFFFAOYSA-N Fc(cc1)cc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)c1F Chemical compound Fc(cc1)cc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)c1F JWPFBCRJPHMGGQ-UHFFFAOYSA-N 0.000 description 1
- FSWKNYIWQCOMFX-UHFFFAOYSA-N Fc(cc1F)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1F Chemical compound Fc(cc1F)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1F FSWKNYIWQCOMFX-UHFFFAOYSA-N 0.000 description 1
- NZPFOGAFXJOEPL-UHFFFAOYSA-N Fc(ccc(C1Nc2ccccc2-c2ccnc3c2c1c[nH]3)c1F)c1F Chemical compound Fc(ccc(C1Nc2ccccc2-c2ccnc3c2c1c[nH]3)c1F)c1F NZPFOGAFXJOEPL-UHFFFAOYSA-N 0.000 description 1
- DQKOEJAKTBEUII-UHFFFAOYSA-N Fc1c(C(c2c[nH]3)Nc(cccc4)c4-c4c2c3ncc4)cccn1 Chemical compound Fc1c(C(c2c[nH]3)Nc(cccc4)c4-c4c2c3ncc4)cccn1 DQKOEJAKTBEUII-UHFFFAOYSA-N 0.000 description 1
- PRZXJAIFSLWDCR-UHFFFAOYSA-N Fc1cc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc(F)c1 Chemical compound Fc1cc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc(F)c1 PRZXJAIFSLWDCR-UHFFFAOYSA-N 0.000 description 1
- ADQWZEJYOPEHOF-UHFFFAOYSA-N Fc1cc(Cl)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1 Chemical compound Fc1cc(Cl)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1 ADQWZEJYOPEHOF-UHFFFAOYSA-N 0.000 description 1
- UBHBMONOIRNUJF-UHFFFAOYSA-N Fc1cc(F)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1 Chemical compound Fc1cc(F)c(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)cc1 UBHBMONOIRNUJF-UHFFFAOYSA-N 0.000 description 1
- OSJBWAPYRGIWII-UHFFFAOYSA-N Fc1cccc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)c1F Chemical compound Fc1cccc(C(c2c[nH]3)Nc4ccccc4-c4c2c3ncc4)c1F OSJBWAPYRGIWII-UHFFFAOYSA-N 0.000 description 1
- XFZIBBJICPJLMJ-UHFFFAOYSA-N Fc1cccc(Cl)c1C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3 Chemical compound Fc1cccc(Cl)c1C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3 XFZIBBJICPJLMJ-UHFFFAOYSA-N 0.000 description 1
- SQENUGNVGCTABM-UHFFFAOYSA-N OC(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)=O Chemical compound OC(C(c1c[nH]2)Nc3ccccc3-c3c1c2ncc3)=O SQENUGNVGCTABM-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- SOVRHBFGUWDKKW-UHFFFAOYSA-N [O-][N+](c1c(C2Nc3ccccc3-c3ccnc4c3c2c[nH]4)cccc1)=O Chemical compound [O-][N+](c1c(C2Nc3ccccc3-c3ccnc4c3c2c[nH]4)cccc1)=O SOVRHBFGUWDKKW-UHFFFAOYSA-N 0.000 description 1
- CUOFXLXWOAEHGY-UHFFFAOYSA-N c([nH]c1ncc2)c3c1c2-c1ccccc1NC3c1cnccc1 Chemical compound c([nH]c1ncc2)c3c1c2-c1ccccc1NC3c1cnccc1 CUOFXLXWOAEHGY-UHFFFAOYSA-N 0.000 description 1
- UPJZSWHGAMYVKL-UHFFFAOYSA-N c([nH]c1ncc2)c3c1c2-c1ccccc1NC3c1ncccc1 Chemical compound c([nH]c1ncc2)c3c1c2-c1ccccc1NC3c1ncccc1 UPJZSWHGAMYVKL-UHFFFAOYSA-N 0.000 description 1
- NGSGFCQHFWSVGJ-UHFFFAOYSA-N c1c(C(c2ccccc2)Nc2ccccc2-2)c3c-2ncnc3[nH]1 Chemical compound c1c(C(c2ccccc2)Nc2ccccc2-2)c3c-2ncnc3[nH]1 NGSGFCQHFWSVGJ-UHFFFAOYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85586206P | 2006-11-01 | 2006-11-01 | |
| PCT/US2007/083134 WO2008079521A2 (en) | 2006-11-01 | 2007-10-31 | Tricyclic heteroaryl compounds useful as inhibitors of janus kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010508363A JP2010508363A (ja) | 2010-03-18 |
| JP2010508363A5 true JP2010508363A5 (OSRAM) | 2011-12-15 |
Family
ID=39561862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535437A Pending JP2010508363A (ja) | 2006-11-01 | 2007-10-31 | ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8163732B2 (OSRAM) |
| EP (1) | EP2079740B1 (OSRAM) |
| JP (1) | JP2010508363A (OSRAM) |
| KR (1) | KR20090082453A (OSRAM) |
| CN (1) | CN101568540A (OSRAM) |
| AU (1) | AU2007338574A1 (OSRAM) |
| CA (1) | CA2668159A1 (OSRAM) |
| IL (1) | IL198510A0 (OSRAM) |
| MX (1) | MX2009004771A (OSRAM) |
| NO (1) | NO20092130L (OSRAM) |
| RU (1) | RU2009120622A (OSRAM) |
| WO (1) | WO2008079521A2 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2764885C (en) * | 2009-06-08 | 2018-05-15 | Takeda Pharmaceutical Company Limited | Dihydropyrrolonaphtyridinone compounds as inhibitors of jak |
| KR101438293B1 (ko) * | 2009-09-21 | 2014-09-05 | 에프. 호프만-라 로슈 아게 | Ｊａｋ의 매크로사이클릭 억제자 |
| WO2012078802A1 (en) * | 2010-12-08 | 2012-06-14 | Takeda Pharmaceutical Company Limited | PREPARATION OF SUBSTITUTED-4,5-DIHYDROPYRROLO[4,3,2-de][2,6]NAPHTHYRIDIN-3(1H)-ONES |
| WO2012085176A1 (en) * | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| CA2856722C (en) * | 2011-11-30 | 2022-11-22 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| CN108440528A (zh) * | 2013-03-12 | 2018-08-24 | 艾伯维公司 | 四环布罗莫结构域抑制剂 |
| EP3057972A4 (en) * | 2013-10-15 | 2017-03-22 | V Jin | Novel compositions, uses and methods for their preparation |
| WO2015119712A1 (en) * | 2014-02-06 | 2015-08-13 | Abbvie Inc. | Tetracyclic cdk9 kinase inhibitors |
| WO2016004272A1 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| WO2018213211A1 (en) * | 2017-05-15 | 2018-11-22 | The Regents Of The University Of Michigan | Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors |
| EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| EP3955920A1 (en) | 2019-04-16 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE69928414T2 (de) * | 1998-09-18 | 2006-08-03 | Abbott Gmbh & Co. Kg | 4-aminopyrrolopyrimidine als kinaseinhibitoren |
| EP1399440B1 (en) * | 2001-06-15 | 2009-06-03 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| KR20050013562A (ko) * | 2002-05-30 | 2005-02-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ｊａｋ 및 ｃｄｋ2 프로테인 키나아제의 억제제 |
| EP2332940B1 (en) * | 2004-03-30 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| EP1781654A1 (en) * | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| KR20070104641A (ko) | 2005-02-03 | 2007-10-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로 유용한 피롤로피리미딘 |
| ES2345629T3 (es) * | 2005-05-16 | 2010-09-28 | Irm Llc | Derivados de pirrolopiridina como inhibidores de proteina quinasas. |
-
2007
- 2007-10-31 EP EP07872337A patent/EP2079740B1/en not_active Not-in-force
- 2007-10-31 JP JP2009535437A patent/JP2010508363A/ja active Pending
- 2007-10-31 CA CA002668159A patent/CA2668159A1/en not_active Abandoned
- 2007-10-31 AU AU2007338574A patent/AU2007338574A1/en not_active Abandoned
- 2007-10-31 CN CNA2007800480929A patent/CN101568540A/zh active Pending
- 2007-10-31 MX MX2009004771A patent/MX2009004771A/es active IP Right Grant
- 2007-10-31 RU RU2009120622/04A patent/RU2009120622A/ru not_active Application Discontinuation
- 2007-10-31 KR KR1020097011345A patent/KR20090082453A/ko not_active Withdrawn
- 2007-10-31 WO PCT/US2007/083134 patent/WO2008079521A2/en not_active Ceased
-
2009
- 2009-05-01 US US12/434,154 patent/US8163732B2/en not_active Expired - Fee Related
- 2009-05-03 IL IL198510A patent/IL198510A0/en unknown
- 2009-06-02 NO NO20092130A patent/NO20092130L/no not_active Application Discontinuation
-
2012
- 2012-03-26 US US13/429,826 patent/US20130090331A1/en not_active Abandoned
-
2014
- 2014-01-27 US US14/164,419 patent/US20140206671A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508363A5 (OSRAM) | ||
| RU2009120622A (ru) | Трициклические гетероарильные соединения в качестве ингибиторов янус-киназы | |
| JP2010520264A5 (OSRAM) | ||
| KR102547188B1 (ko) | 테트라하이드로피라닐 아미노-피롤로피리미디논 및 이의 사용 방법 | |
| JP5403709B2 (ja) | 新規なトリサイクリック誘導体またはその薬学的に許容可能な塩、それらの製造方法およびそれらを含む薬学的組成物 | |
| JP2020520924A5 (OSRAM) | ||
| US20090099168A1 (en) | HIV Integrase inhibitors | |
| JP2010540562A5 (OSRAM) | ||
| JP2016500112A (ja) | ラパマイシン類似体及びその製作方法 | |
| KR20170034889A (ko) | 화합물 | |
| JP2010522210A5 (OSRAM) | ||
| JP2010513386A5 (OSRAM) | ||
| KR20090106633A (ko) | ＰＤＥ5 억제제로서 유용한 6-벤질-2,3,4,7-테트라히드로-인돌로[2,3-ｃ]퀴놀린 화합물 | |
| JP2018515509A (ja) | ウイルス感染の治療及び予防のための新規なスルホンイミドイルプリノン化合物及び誘導体 | |
| JP2006517976A5 (OSRAM) | ||
| CN112409294A (zh) | 苯并噻嗪酮衍生物及其制备方法与作为抗结核药物的应用 | |
| US9458164B2 (en) | Pyrrolopyridazines as potassium ion channel inhibitors | |
| JPH05112572A (ja) | １−（ピリド〔３，４−ｂ〕−１，４−オキサジニル−４−イル）−１Ｈ−インドール類 | |
| JP5847362B1 (ja) | シクロヘキシルピリジン誘導体 | |
| JP7620091B2 (ja) | 縮合環ジイミド誘導体、その製造方法と使用 | |
| DE60226225T2 (de) | Phtalazine derivate mit angiogenesis inhibierender wirkung | |
| CN105829321B (zh) | 用于治疗癌症和炎性疾病的化合物 | |
| JP6464244B2 (ja) | Ｔｅｒｔ−ブチル ｎ−［２−｛４−［６−アミノ−５−（２，４−ジフルオロベンゾイル）−２−オキソピリジン−１（２ｈ）−イル］−３，５−ジフルオロフェニル｝エチル）−ｌ−アラニネート又はその製薬上許容され得る塩、水和物もしくは溶媒和物 | |
| DE68910593T2 (de) | Chinolinoncarbonsäuren. | |
| US20160346296A1 (en) | Substituted triazolobenzodiazepines |